Effect on Insulin-Stimulated Release of D-Chiro-Inositol-Containing Inositolphosphoglycan Mediator During Weight Loss in Obese Women with and Without Polycystic Ovary Syndrome

Overview

Journal Int J Endocrinol

Publisher Wiley

Specialty Endocrinology

Date 2016 Oct 11

PMID 27721826

Citations 2

Authors

Kai I Cheang

Sakita N Sistrun

Kelley S Morel

John E Nestler

Affiliations

Soon will be listed here.

Abstract

A deficiency of D-chiro-inositol-inositolphosphoglycan mediator (DCI-IPG) may contribute to insulin resistance in polycystic ovary syndrome (PCOS). Whether the relationship between impaired DCI-IPG release and insulin resistance is specific to PCOS rather than obesity is unknown. We assessed insulin-released DCI-IPG and its relationship to insulin sensitivity at baseline and after weight loss in obese women with and without PCOS. Obese PCOS ( = 16) and normal ( = 15) women underwent 8 weeks of a hypocaloric diet. The Matsuda index, area under the curve DCI-IPG (AUC), AUC, and AUC/AUC were measured during a 2 hr OGTT at baseline and 8 weeks. PCOS women had lower AUC/AUC at baseline and a significant relationship between AUC/AUC and Matsuda index ( = 0.0003), which was not present in controls. Weight loss was similar between PCOS (-4.08 kg) and normal women (-4.29 kg, = 0.6281). Weight loss in PCOS women did not change the relationship between AUC/AUC and Matsuda index ( = 0.0100), and this relationship remained absent in control women. The association between AUC/AUC and insulin sensitivity was only found in PCOS but not in normal women, and this relationship was unaffected by weight loss. DCI and its messenger may contribute to insulin resistance in PCOS independent of obesity.

Citing Articles

The Effect of a Very-Low-Calorie Diet (VLCD) vs. a Moderate Energy Deficit Diet in Obese Women with Polycystic Ovary Syndrome (PCOS)-A Randomised Controlled Trial.

Deshmukh H, Papageorgiou M, Wells L, Akbar S, Strudwick T, Deshmukh K Nutrients. 2023; 15(18).

PMID: 37764656 PMC: 10536436. DOI: 10.3390/nu15183872.

Weight Management Interventions in Women with and without PCOS: A Systematic Review.

Kataoka J, Tassone E, Misso M, Joham A, Stener-Victorin E, Teede H Nutrients. 2017; 9(9).

PMID: 28885578 PMC: 5622756. DOI: 10.3390/nu9090996.

References

Gupta A, Jakubowicz D, Nestler J . Pioglitazone Therapy Increases Insulin-Stimulated Release of d-Chiro-Inositol-Containing Inositolphosphoglycan Mediator in Women with Polycystic Ovary Syndrome. Metab Syndr Relat Disord. 2016; 14(8):391-396. PMC: 5073216. DOI: 10.1089/met.2016.0009. View

Baillargeon J, Iuorno M, Jakubowicz D, Apridonidze T, He N, Nestler J . Metformin therapy increases insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2004; 89(1):242-9. DOI: 10.1210/jc.2003-030437. View

Baillargeon J, Diamanti-Kandarakis E, Ostlund Jr R, Apridonidze T, Iuorno M, Nestler J . Altered D-chiro-inositol urinary clearance in women with polycystic ovary syndrome. Diabetes Care. 2006; 29(2):300-5. DOI: 10.2337/diacare.29.02.06.dc05-1070. View

Knochenhauer E, Key T, Kahsar-Miller M, Waggoner W, Boots L, Azziz R . Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab. 1998; 83(9):3078-82. DOI: 10.1210/jcem.83.9.5090. View

Boule N, Weisnagel S, Lakka T, Tremblay A, Bergman R, Rankinen T . Effects of exercise training on glucose homeostasis: the HERITAGE Family Study. Diabetes Care. 2004; 28(1):108-14. DOI: 10.2337/diacare.28.1.108. View

Iuorno M, Jakubowicz D, Baillargeon J, Dillon P, Gunn R, Allan G . Effects of d-chiro-inositol in lean women with the polycystic ovary syndrome. Endocr Pract. 2004; 8(6):417-23. DOI: 10.4158/EP.8.6.417. View

Nestler J, Jakubowicz D, Reamer P, Gunn R, Allan G . Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med. 1999; 340(17):1314-20. DOI: 10.1056/NEJM199904293401703. View

Moran L, Hutchison S, Norman R, Teede H . Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2011; (2):CD007506. DOI: 10.1002/14651858.CD007506.pub2. View

Romero G, Larner J . Insulin mediators and the mechanism of insulin action. Adv Pharmacol. 1993; 24:21-50. DOI: 10.1016/s1054-3589(08)60932-1. View

10.

Baillargeon J, Iuorno M, Apridonidze T, Nestler J . Uncoupling between insulin and release of a D-chiro-inositol-containing inositolphosphoglycan mediator of insulin action in obese women With polycystic ovary syndrome. Metab Syndr Relat Disord. 2010; 8(2):127-36. PMC: 3140116. DOI: 10.1089/met.2009.0052. View

11.

Asplin I, Galasko G, Larner J . chiro-inositol deficiency and insulin resistance: a comparison of the chiro-inositol- and the myo-inositol-containing insulin mediators isolated from urine, hemodialysate, and muscle of control and type II diabetic subjects. Proc Natl Acad Sci U S A. 1993; 90(13):5924-8. PMC: 46839. DOI: 10.1073/pnas.90.13.5924. View

12.

Hoeger K, Kochman L, Wixom N, Craig K, Miller R, Guzick D . A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertil Steril. 2004; 82(2):421-9. DOI: 10.1016/j.fertnstert.2004.02.104. View

13.

Lagana A, Barbaro L, Pizzo A . Evaluation of ovarian function and metabolic factors in women affected by polycystic ovary syndrome after treatment with D-Chiro-Inositol. Arch Gynecol Obstet. 2014; 291(5):1181-6. DOI: 10.1007/s00404-014-3552-6. View

14.

Moran L, Noakes M, Clifton P, Tomlinson L, Galletly C, Norman R . Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003; 88(2):812-9. DOI: 10.1210/jc.2002-020815. View

15.

Evangelou P, Tzotzas T, Christou G, Elisaf M, Kiortsis D . Does the presence of metabolic syndome influence weight loss in obese and overweight women?. Metab Syndr Relat Disord. 2010; 8(2):173-8. DOI: 10.1089/met.2009.0066. View

16.

McLaughlin T, Abbasi F, Carantoni M, Schaaf P, Reaven G . Differences in insulin resistance do not predict weight loss in response to hypocaloric diets in healthy obese women. J Clin Endocrinol Metab. 1999; 84(2):578-81. DOI: 10.1210/jcem.84.2.5441. View

17.

Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale H, Futterweit W . Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab. 2006; 91(11):4237-45. DOI: 10.1210/jc.2006-0178. View

18.

Shashkin P, Shashkina E, Fernqvist-Forbes E, Zhou Y, Grill V, Katz A . Insulin mediators in man: effects of glucose ingestion and insulin resistance. Diabetologia. 1997; 40(5):557-63. DOI: 10.1007/s001250050715. View

19.

Sodergard R, Backstrom T, Shanbhag V, Carstensen H . Calculation of free and bound fractions of testosterone and estradiol-17 beta to human plasma proteins at body temperature. J Steroid Biochem. 1982; 16(6):801-10. DOI: 10.1016/0022-4731(82)90038-3. View

20.

Sigal R, El-Hashimy M, Martin B, Soeldner J, Krolewski A, Warram J . Acute postchallenge hyperinsulinemia predicts weight gain: a prospective study. Diabetes. 1997; 46(6):1025-9. DOI: 10.2337/diab.46.6.1025. View